Publications
179
Citations
38,071
Est. group size
~14
Recurring co-author estimate
Active years
30
Publishing since 1996
Typically publishes in teams of ~20 · 0% small-team papers (≤3 authors) · across 19 venues
- P2 Healthcare Resource Utilization (HCRU) and Cost among Patients with Metastatic Melanoma Receiving Nivolumab + Relatlimab (NIVO+RELA) or Nivolumab + Ipilimumab (NIVO+IPI) in the Optum Database
Value in Health · 2025
- Nivolumab With or Without Ipilimumab in Patients With Recurrent or Metastatic Merkel Cell Carcinoma: A Nonrandomized, Open-Label, International, Multicenter Phase I/II Study
Journal of Clinical Oncology · 2025
- Dual anti-CTLA-4 and anti-PD-1 blockade in metastatic basal cell carcinoma
npj Precision Oncology · 2025
- Comparative Analysis of Intracranial Response Assessment Criteria in Patients With Melanoma Brain Metastases Treated With Combination Nivolumab + Ipilimumab in CheckMate 204
Journal of Clinical Oncology · 2025
- Analysis of treatment-free survival of patients with advanced melanoma receiving nivolumab as monotherapy or in combination with relatlimab in RELATIVITY-047
Journal for ImmunoTherapy of Cancer · 2025
- Erratum: First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data
Journal of Clinical Oncology · 2025
- Efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO + RELA) versus NIVO plus ipilimumab (NIVO + IPI) in advanced melanoma: An updated indirect treatment comparison (ITC) with 4-year follow-up data.
Journal of Clinical Oncology · 2025
- Real-world comparison of survival with nivolumab (NIVO) + relatlimab (RELA) vs NIVO + ipilimumab (IPI) in advanced melanoma.
Journal of Clinical Oncology · 2025
- Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma
New England Journal of Medicine · 2024
- Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047
Journal of Clinical Oncology · 2024
- Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1–2, open-label, multicohort trial
The Lancet Oncology · 2024
- First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data
Journal of Clinical Oncology · 2024
- Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma
Journal of Clinical Oncology · 2024
- LBA43 10-y survival outcomes from the phase III CheckMate 067 trial of nivolumab plus ipilimumab in advanced melanoma
Annals of Oncology · 2024
- Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma (RELATIVITY-047): Overall survival (OS) and melanoma-specific survival (MSS) outcomes at 3 years.
Journal of Clinical Oncology · 2024
- Journal of Clinical Oncology×43
- Annals of Oncology×11
- New England Journal of Medicine×5
- Journal for ImmunoTherapy of Cancer×5
- Neuro-Oncology×3
- Douglas B. Johnson
Medicine · University of Michigan
- Leslie A. Fecher
Medicine · University of Michigan
- Kari Kendra
Medicine · The Ohio State University
- Siming Li
Medicine · University of Michigan
- T. Vincent
Medicine · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile